Pål Stenmark

Pål Stenmark


Visa sidan på svenska
Works at Department of Biochemistry and Biophysics
Telephone 08-16 37 29
Visiting address Svante Arrhenius väg 16
Room A 467
Postal address Institutionen för biokemi och biofysik 106 91 Stockholm


Structural and biophysical studies of Botulinum neurotoxins and novel Cancer targets in nucleotide metabolism

- The botulinum neurotoxins

The botulinum neurotoxins are the most toxic substances known; they are one million times more toxic than the cobra toxin. In spite of their extreme toxicity there has been a rapid expansion of the medical applications for the botulinum neurotoxins, with new applications constantly being discovered. This line of treatment is becoming the standard procedure for many conditions. The toxins are possible agents for bioterrorism and the development of countermeasures and vaccines are of high priority. We are studying the toxins using a wide variety of methods, including X-ray crystallography, to understand toxins basic mechanism and to improve their therapeutic properties. 



Structure of Botulinum neurotoxin type B bound to two receptors on the neuronal


- Structure based drug design targeting cancer

We also study enzymes involved in the nucleotide metabolism. One example is MTH1, this protein is important for clearing oxidative damage from the nucleotide pool. Many types of cancer cells have high levels of oxidative damage and depend on MTH1 for survival. We use X-ray crystallography to study the binding of MTH1 to natural substrates and potent inhibitors that we are developing in an interdisciplinary research collaboration. We use structural based drug design to refine these inhibitors into novel cancer drugs.


The crystal structure of human MTH1 in complex with a key inhibitor.


Group members

Sarah Linton, Laboratory Assistant

Geoffrey Masuyer, Postdoc

Emma Rose Scaletti, Postdoc

Robert Gustafsson, PhD Student

Linda Henriksson, PhD Student

Markel Martinez, PhD Student

Daniel Rehling, PhD Student


Selected Publications

  • Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita S, Martínez-Carranza M, Dong M, Stenmark P. (2017)
    Identification and characterization of a novel botulinum neurotoxin
    Nature Communications. 2017 Aug 3;8:14130.

  • Masuyer G, Conrad J, Stenmark P. (2017)
    The structure of the tetanus toxin reveals pH-mediated domain dynamics.
    EMBO Reports. 2017 Aug;18(8):1306-1317. 

  • Gustafsson R, Jemth AS, Gustafsson NM, Färnegårdh K, Loseva O, Wiita E, Bonagas N, Dahllund L, Llona-Minguez S, Häggblad M, Henriksson M, Andersson Y, Homan E, Helleday T, Stenmark P(2017)
    Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor.
    Cancer Research. 2017 Feb 15;77(4):937-948.

  • Carter M, Jemth AS, Hagenkort A, Page BD, Gustafsson R, Griese JJ, Gad H, Valerie NC, Desroses M, Boström J, Warpman Berglund U, Helleday T, Stenmark P(2015)
    Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2.
    Nature Communications. 2015 Aug 4;6:7871.

  • Gad H, Koolmeister T, Jemth A, Eshtad S, Jacques S, Ström C, Svensson
    L, Schultz N, Lundbäck T, Einarsdottir, Saleh A, Göktürk C,
    Baranczewski P, Svensson R, Berntsson R, Gustafsson R, Strömberg K,
    Sanjiv K, Jacques-Cordonnier M, Desroses M, Gustavsson A, Olofsson R,
    Johansson F, Homan E, Loseva O, Bräutigam L, Johansson L, Höglund A, Hagenkort A, Pham T, Altun M, Gaugaz F, Vikingsson S, Evers B,
    Henriksson M, Vallin K, Wallner O, Hammarström L, Wiita E, Almlöf E,
    Kaldéren C, Axelsson H, Puigvert J, Häggblad M, Jeppsson F, Martens U, Lundin C, Lundgren B, Granelli I, Jenmalm-Jensen A, Artursson P,
    Nilsson J, Stenmark P, Scobie M, Warpman-Berglund U, Helleday T. (2014)
    MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
    Nature. 2014 Apr 10;508(7495):215-21.

  • Berntsson RP, Peng L, Dong M, Stenmark P(2013)
    Structure of dual receptor binding to botulinum neurotoxin B.
    Nature communications, 2013 Jun 28;4:2058


Funding Sources

Our research is supported by grants from the Swedish Research Council, the Wenner-Gren Foundations, the Carl Tryggers foundation, The Knut and Alice Wallenberg Foundation and the Swedish Cancer Society. 

Last updated: October 17, 2017

Bookmark and share Tell a friend